HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Lyell Immunopharma in a research note issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.20). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma Trading Down 3.4 %

NASDAQ LYEL opened at $0.59 on Monday. The company has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.91. Lyell Immunopharma has a 12-month low of $0.51 and a 12-month high of $3.15. The company has a market cap of $172.83 million, a P/E ratio of -0.74 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently bought and sold shares of the business. Centiva Capital LP acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at $31,000. Graham Capital Management L.P. acquired a new stake in Lyell Immunopharma in the 4th quarter valued at $33,000. RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at $42,000. Intech Investment Management LLC purchased a new position in Lyell Immunopharma during the 3rd quarter worth $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth $52,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.